Rapid Generation of Human Therapuetic Antibodies Against Influenza

快速产生人类流感治疗抗体

• 批准号: 7480790
• 负责人: YOSEF REFAELI
• 金额: $ 18.07万
• 依托单位: TAIGA BIOTECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-15 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7480790
• 关键词: Adult; Antibodies; Antibody Formation; Antibody Specificity; Antibody-Producing Cells; Antigenic Specificity; Antigens; Autoantibodies; Autoantigens; B Cell Proliferation; B-Lymphocytes; Binding; Biological; Biological Process; Bone Marrow Stem Cell; Cell Line; Cell Lineage; Cells; Chimeric Proteins; Clinic; Consensus Sequence; DNA; Face; Future; Generations; Glycoproteins; Goals; H5 hemagglutinin; HIV-1; Health; Hemagglutinin; Hematopoietic stem cells; Human; Immune; Immune Complex Diseases; Immune response; Immunization; Individual; Infection prevention; Influenza; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A virus; Kidney; Lymphoma; Malaria; Membrane Proteins; Methods; Monoclonal Antibodies; Mus; Neuraminidase; Numbers; Passive Immunization; Personal Satisfaction; Persons; Phase; Phenotype; Principal Investigator; Process; Production; Protein Overexpression; Public Health; Receptors, Antigen, B-Cell; Role; Science; Signal Transduction; Specificity; Staging; System; T-Lymphocyte; Technology; Testing; Therapeutic; Therapeutic Agents; Therapeutic Intervention; Therapeutic antibodies; Time; Transduction Gene; Transgenic Mice; Transgenic Organisms; Tuberculosis; Umbilical Cord Blood; Vaccines; Viral; Virus; Virus Diseases; aged; anti-influenza; clinical application; cytokine; human adult stem cell; human monoclonal antibodies; influenzavirus; mouse model; neutralizing antibody; novel; novel strategies; pandemic disease; pandemic influenza; programs; research study; response; vaccination strategy

DESCRIPTION (provided by applicant): Using a method of retroviral gene transduction we have been able to generate conditionally immortalized long-term hematopoietic stem cell lines from mouse bone marrow stem cells, fetal cord blood and adult bone marrow stem cells. Phase I of this project includes testing existing mouse antibodies against Influenza for their ability to neutralize pathogenic strains of Influenza and adapting this technology to generate human antibodies against Influenza in a mouse model using human adult stem cells. Phase II of the project will involve optimizing large-scale production and testing of human anti-influenza antibodies. PUBLIC HEALTH RELEVANCE: This project seeks to optimize a novel method to rapidly generate human therapeutic antibodies against the Influenza virus in a mouse model using human adult stem cell lines. Once this method has been validated for Influenza, the long-term goal to benefit public health will be to use this system to generate antibodies for clinical applications in a variety of global health issues including, but not limited to, HIV-1, tuberculosis and malaria.

描述（由申请人提供）：使用逆转录病毒基因转导的方法，我们已经能够从小鼠骨髓干细胞、胎儿脐带血和成人骨髓干细胞产生条件永生化的长期造血干细胞系。该项目的第一阶段包括测试现有的小鼠抗流感抗体中和流感致病菌株的能力，并采用该技术在小鼠模型中使用人类成体干细胞产生抗流感的人类抗体。该项目的第二阶段将涉及优化人类抗流感抗体的大规模生产和测试。公共卫生相关性：该项目旨在优化一种新的方法，使用人类成体干细胞系在小鼠模型中快速产生针对流感病毒的人类治疗性抗体。一旦这种方法被验证用于流感，有益于公共卫生的长期目标将是使用这种系统产生用于各种全球健康问题的临床应用的抗体，包括但不限于HIV-1，结核病和疟疾。